We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 μL 
| EXPERIMENTAL DESIGN
In a monocentric prospective study, we investigated the plasma levels of PMPs by flow cytometry and evaluated their thrombogenic activity by measuring the clotting time (3, s4, s5) . We also evaluated the link between PMPs circulating levels and tumor burden calculated by RECIST criteria and radiography contouring (supplementary Materials and Methods). Ninety patients (29 women and 61 men) with cutaneous metastatic melanoma, including 45 AJCC stage III and 45 AJCC stage IV melanoma were investigated.
| RESULTS
There was a significant difference between the plasma levels of PMPs in patients with stage III and in stage IV melanoma ( well understood, but it seems that there is a direct activation by the tumoral cells releasing procoagulant molecules such as the tissue factor [2] as well as an indirect activation by immune cells. [5, 6] In our study, we did not find any association between the plasma level of PMPs and tumor burden using RECIST criteria or radiographic contouring, for all sizes of PMPs in patients with stage IV melanoma. We do not have any clear explanation but we may hypothesise that PMPs reflect the tumor microenvironment, including angiogenesis, inflammatory reaction and antitumoral immunity rather than tumor burden. [5] It may also be suggested that PMPs may not be representative of tumor burden as recently suggested by Willms et al. [4] Cancer-associated venous thromboembolism constitutes the second cause of death after cancer. [7] We previously observed an inverse correlation between PMPs and clotting times with a lower clotting time in stage IV patients as compared to stage III patients. [3] In the present study, we confirmed that the procoagulant activity of PMPs was also significantly higher in patients with stage IV melanoma as compared to patients with stage III melanoma.
In conclusion, although we cannot conclude on the cell origin, that . The area under the curve was 0.852. This level was associated with a sensitivity of 73.3%, a specificity of 93.3%, a positive predictive value of 91.7% and a negative predictive value of 77.8%.
| BACKGROUND
The skin, the largest organ of the human body, is the first line of protection against pathogens, physical and chemical injuries. It is a major immunological organ with an important density of antigenpresenting cells (APC), [1] able to capture pathogens through endocytic pathways and exhibiting cross-presentation ability. In addition, the skin tissue contains a large pool of T cells, mostly memory T cells expressing the skin-homing marker CLA (cutaneous lymphocyte antigen) and displaying long-term immune protection capacity. [2, 3] These are features highly desirable for induction of vaccination and tissue maintenance of immune protection. We previously demonstrated that delivery of vaccine via the skin allows for the generation of a potent CD8 T-cell response and the induction of a humoral 
